Old Web
English
Sign In
Acemap
>
authorDetail
>
Steve Blotner
Steve Blotner
Hoffmann-La Roche
Pharmacodynamics
Medicine
Pharmacokinetics
Pharmacology
Dosing
5
Papers
187
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
2012
Clinical Cancer Research
Maria Martinez-Garcia
Udai Banerji
Joan Albanell
Rastilav Bahleda
Saoirse O. Dolly
Françoise Kraeber-Bodéré
Federico Rojo
E. Routier
Ernesto Guarin
Zhi Xin Xu
Ruediger Rueger
Jean Tessier
Eliezer Shochat
Steve Blotner
Valerie Meresse Naegelen
Jean-Charles Soria
Show All
Source
Cite
Save
Citations (109)
Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors
2012
Clinical Cancer Research
Suzanne Leijen
Mark R. Middleton
Patricia Tresca
Françoise Kraeber-Bodéré
V. Diéras
M. E. Scheulen
Avinash Gupta
Vanesa Lopez-Valverde
Zhi Xin Xu
Ruediger Rueger
Jean Tessier
Eliezer Shochat
Steve Blotner
Valerie Meresse Naegelen
Jan H. M. Schellens
Wilfried Eberhardt
Show All
Source
Cite
Save
Citations (57)
First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors.
2011
Journal of Clinical Oncology
Saoirse O. Dolly
Joan Albanell
Françoise Kraeber-Bodéré
Udai Banerji
R. Bahleda
M Martínez García
Zhonghui Xu
Ernesto Guarin
Jean Tessier
Eliezer Shochat
J Deutsch
Steve Blotner
Valerie Meresse
José Soria
Show All
Source
Cite
Save
Citations (5)
Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor.
2011
Journal of Clinical Oncology
Suzanne Leijen
Mark R. Middleton
Patricia Tresca
Françoise Kraeber-Bodéré
V. Diéras
M. E. Scheulen
Jean Tessier
Zhonghui Xu
Eliezer Shochat
A Walz
J Deutsch
Steve Blotner
V. Lopez Valverde
Valerie Meresse Naegelen
Jan H. M. Schellens
Wilfried Eberhardt
Show All
Source
Cite
Save
Citations (7)
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of RO5068760, an MEK Inhibitor, in Healthy Volunteers: Assessment of Target Suppression
2010
The Journal of Clinical Pharmacology
Lucy Lee
Huifeng Niu
Petra Goelzer
Ruediger Rueger
Jonathan Deutsch
Rachel Busse‐Reid
Stefanie DeSchepper
Steve Blotner
Joanne Barrett
Georges Weissgerber
Richard Peck
Show All
Source
Cite
Save
Citations (9)
1